1-2 of 2
Laura Vitale
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O'Rourke, David D. Tran, Karen L. Fink, Louis B. Nabors, Gordon Li, Daniela A. Bota, Rimas V. Lukas, Lynn S. Ashby, J. Paul Duic, Maciej M. Mrugala, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A. Green, Michael J. Yellin, Christopher D. Turner, Tibor Keler, Thomas A. Davis, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1586–1594.
https://doi.org/10.1158/1078-0432.CCR-18-1140
Published: 01 April 2020
View article titled, Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Open the PDF for Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

Michael A. Morse, Robert Chapman, John Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, Renee Riggs, Li-Zhen He, Venky Ramakrishna, Laura Vitale, Biwei Zhao, Stephen A. Butler, Amy Hobeika, Takuya Osada, Thomas Davis, Timothy Clay, H. Kim Lyerly
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4844–4853.
https://doi.org/10.1158/1078-0432.CCR-11-0891
Published: 17 July 2011
View article titled, Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients
Open the PDF for Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients in another window
Includes: Supplementary data